Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Keros Therapeutics. The associated price target remains the same with $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith has given his Buy rating due to a combination of factors related to Keros Therapeutics’ strategic decisions and clinical developments. The company has chosen to prioritize the development of KER-065 for Duchenne Muscular Dystrophy (DMD), which is seen as a wise move given the challenges faced with their other pipeline candidate, cibotercept, following issues in its Phase 2 trial for pulmonary arterial hypertension.
The decision to focus on KER-065 is supported by promising Phase 1 trial results that showed increases in lean body mass and improvements in metabolic markers, suggesting potential therapeutic benefits for DMD patients. Additionally, the company plans to engage with regulators to design a Phase 2 trial for KER-065, indicating a clear path forward. These strategic shifts, along with leadership changes aimed at streamlining operations, contribute to the perception of underappreciated value in Keros Therapeutics’ stock, justifying the Buy rating.
Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Sagimet Biosciences, Inc. Class A, and MoonLake Immunotherapeutics. According to TipRanks, Smith has an average return of 43.9% and a 53.07% success rate on recommended stocks.